Download PDF
Angewandte Nuklearmedizin 2022; 45(04): 273-277
DOI: 10.1055/a-1712-6095
Nuklearmedizinische Hirnbildgebung
Übersicht

Tau-PET Bildgebung der Bewegungsstörungen

Tau-PET imaging in movement disorders
Leonie Beyer
1   Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
,
Matthias Brendel
1   Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
2   German Center for Neurodegenerative Diseases (DZNE), Munich
3   Munich Cluster for Systems Neurology (SyNergy), Munich
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Innerhalb der Bewegungsstörungen bilden die Tauopathien eine heterogene Gruppe neurodegenerativer Erkrankungen ab, zu denen die Progressive supranukläre Blickparese (PSP) und die kortikobasale Degeneration (CBD) zählen. Seit mehr als 10 Jahren werden tau-spezifische Radiotracer zur Verwendung mittels Positronen-Emissions-Tomografie (PET) entwickelt. Während Tau-PET-Radioliganden der ersten Generation nur einen moderaten Nutzen bei der Detektion der Bewegungsstörungen mit Tau Pathologie belegen konnten, zeigten weiterentwickelte Tau-PET-Radioliganden ein größeres Potenzial für die Differenzialdiagnostik. Zukünftig könnte die Tau-PET bei Bewegungsstörungen zum Screening bei gegen Tau gerichteten Therapiestudien dienen.

Abstract

Within movement disorders, tauopathies form a heterogeneous group of neurodegenerative diseases, which include progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). For more than 10 years, tau-specific radiotracers have been developed for use with positron emission tomography (PET). While first-generation tau-PET radioligands only showed a moderate benefit in the detection of movement disorders with tau pathology, more advanced tau-PET radioligands showed greater potential for differential diagnostics. In the future, tau-PET could serve as a screening for anti-tau therapy studies in movement disorders.

Schlüsselwörter

tau - PET - Bewegungsstörungen - Parkinson - atypische Parkinsonsyndrome

Keywords

tau - PET - movement disorders - Parkinsonian syndromes


Publication History

Article published online:
02 December 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Levin J, Kurz A, Arzberger T. et al. The Differential Diagnosis and Treatment of Atypical Parkinsonism. Dtsch Arztebl Int 2016; 113: 61-9
    CrossrefPubMedSearch in Google Scholar
  • 2 Mukaetova-Ladinska EB, Harrington CR, Roth M. et al. Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. Am J Pathol 1993; 143: 565-78
    PubMedSearch in Google Scholar
  • 3 Zhao Q, Liu M, Ha L. et al. Quantitative (18)F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients. Front Neurol 2019; 10: 486
    CrossrefPubMedSearch in Google Scholar
  • 4 Lemoine L, Gillberg PG, Svedberg M. et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther 2017; 9: 96
    CrossrefPubMedSearch in Google Scholar
  • 5 Vermeiren C, Motte P, Viot D. et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord 2018; 33: 273-281
    CrossrefPubMedSearch in Google Scholar
  • 6 Ng KP, Pascoal TA, Mathotaarachchi S. et al. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther 2017; 9: 25
    CrossrefPubMedSearch in Google Scholar
  • 7 Leuzy A, Chiotis K, Lemoine L. et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Molecular psychiatry 2019;
    CrossrefPubMedSearch in Google Scholar
  • 8 Aguero C, Dhaynaut M, Normandin MD. et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun 2019; 7: 37
    CrossrefPubMedSearch in Google Scholar
  • 9 Kroth H, Oden F, Molette J. et al. Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies. Eur J Nucl Med Mol Imaging 2019;
    CrossrefPubMedSearch in Google Scholar
  • 10 Honer M, Gobbi L, Knust H. et al. Preclinical Evaluation of (18)F-RO6958948, (11)C-RO6931643, and (11)C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. J Nucl Med 2018; 59: 675-681
    CrossrefPubMedSearch in Google Scholar
  • 11 Zhang W, Tarutani A, Newell KL. et al. Novel tau filament fold in corticobasal degeneration. Nature 2020; 580: 283-287
    CrossrefPubMedSearch in Google Scholar
  • 12 Lowe VJ, Curran G, Fang P. et al. and Murray ME. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 2016; 4: 58
    CrossrefPubMedSearch in Google Scholar
  • 13 Sander K, Lashley T, Gami P. et al. Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement 2016; 12: 1116-1124
    CrossrefPubMedSearch in Google Scholar
  • 14 Soleimani-Meigooni DN, Iaccarino L, La Joie R. et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain 2020;
    CrossrefPubMedSearch in Google Scholar
  • 15 Josephs K, Tosakulwong N, Weigand S. et al. Relationship between (18)F-flortaucipir uptake and histologic lesion types in 4-repeat tauopathies. J Nucl Med 2021;
    CrossrefPubMedSearch in Google Scholar
  • 16 Schonhaut DR, McMillan CT, Spina S. et al. (18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of neurology 2017; 82: 622-634
    CrossrefPubMedSearch in Google Scholar
  • 17 Coakeley S, Cho SS, Koshimori Y. et al. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. J Cereb Blood Flow Metab 2017; 37: 3150-3160
    CrossrefPubMedSearch in Google Scholar
  • 18 Smith R, Schöll M, Widner H. et al. In vivo retention of (18)F-AV-1451 in corticobasal syndrome. Neurology 2017; 89: 845-853
    CrossrefPubMedSearch in Google Scholar
  • 19 Brendel M, Barthel H, van Eimeren T. et al. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol 2020; 77: 1408-1419
    CrossrefPubMedSearch in Google Scholar
  • 20 Palleis C, Brendel M, Finze A. et al. Cortical [(18) F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. Mov Disord 2021; 36: 2104-2115
    CrossrefPubMedSearch in Google Scholar
  • 21 Song M, Beyer L, Kaiser L. et al. Binding characteristics of [(18)F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. J Cereb Blood Flow Metab 2021; 41: 2957-2972
    CrossrefPubMedSearch in Google Scholar
  • 22 Song M, Scheifele M, Barthel H. et al. Feasibility of short imaging protocols for [(18)F]PI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging 2021; 48: 3872-3885
    CrossrefPubMedSearch in Google Scholar
  • 23 Tezuka T, Takahata K, Seki M. et al. Evaluation of [(18)F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun 2021; 3: fcab190
    CrossrefPubMedSearch in Google Scholar
  • 24 Franzmeier N, Brendel M, Beyer L. et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nat Commun 2022; 13: 1362
    CrossrefPubMedSearch in Google Scholar
  • 25 Tagai K, Ono M, Kubota M. et al. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. Neuron 2021; 109: 42-58 e8
    CrossrefPubMedSearch in Google Scholar
  • 26 Li L, Liu FT, Li M. et al. Clinical Utility of (18) F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy. Mov Disord 2021; 36: 2314-2323
    CrossrefPubMedSearch in Google Scholar
  • 27 Shi Y, Murzin AG, Falcon B. et al. Cryo-EM structures of tau filaments from Alzheimer's disease with PET ligand APN-1607. Acta neuropathologica 2021; 141: 697-708
    CrossrefPubMedSearch in Google Scholar
  • 28 Lindberg A, Knight AC, Sohn D. et al. Radiosynthesis, In Vitro and In Vivo Evaluation of [(18)F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. ACS Chem Neurosci 2021; 12: 596-602
    CrossrefPubMedSearch in Google Scholar
  • 29 Salloway S, Sperling R. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med 2014; 370: 1460
    CrossrefPubMedSearch in Google Scholar